Cipla Limited (CIPLA) — FY25 Annual Report | 20 June 2025

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla reported a 32% year-on-year revenue increase to ₹87.22 crores for FY 2024-25, driven by strong domestic sales, while net profit declined 15% to ₹12.45 crores due to higher operating costs. The company announced a final dividend of ₹2.50 per share and outlined strategic focus on oncology and respiratory therapies. Material risks include regulatory scrutiny and foreign exchange volatility. Forward guidance emphasized sustained investment in R&D and expansion in emerging markets.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day